February 3-5, 2026 | La Jolla, San Diego, CA

www.lbx-summit.com

FREE TO ATTEND FOR BIOTECH & PHARMA*

10TH ANNIVERSARY

Liquid Biopsy for Precision Oncology Summit

Transforming Precision Therapies Through Robust Liquid Biopsy Testing

Address Translational & Commercial Challenges to Seamlessly Utilize Liquid Biopsy Technologies to Drive Smarter, Accelerated Oncology Drug Development

Expert Speakers Include:

Ildiko Csiki
Chief Medical Officer
Geneos Therapeutics

Claudia Dollins
Vice President, Global Regulatory Affairs
GSK

Michelle Neff
Associate Vice President, Global Regulatory Affairs, Diagnostics
Eli Lilly

Oliver Rosen
Chief Medical Officer
Akamis Bio

Achim Moesta
Executive Director, Head of Oncology Precision Medicine
Regeneron

Steffan Ho
Vice President, Translational Oncology
Pfizer

Proud to Partner With:

FOUNDATION MEDICINE · GUARDANT · natera · Myriad genetics · TEMPUS · CARIS LIFE SCIENCES

+1 617 455 4188 info@hansonwade.com
www.lbx-summit.com Biomarkers & Companion Diagnostics
hansonwade

Celebrating a Decade of the Liquid Biopsy for Precision Oncology Summit

10th Anniversary Liquid Biopsy for Precision Oncology Summit

February 3-5, 2026
La Jolla, San Diego, CA

Liquid biopsies are empowering biopharma leaders to identify actionable mutations, dynamically monitor therapeutic response, and detect minimal residual disease with unparalleled sensitivity. These capabilities are dramatically improving clinical trial efficiency and therapeutic precision; however, alongside this opportunity lies the challenge of embedding liquid biopsies into development workflows that satisfy regulatory requirements, generate payer-relevant evidence, and deliver proven clinical utility.

Celebrating its **10th anniversary**, the **Liquid Biopsy for Precision Oncology Summit** brings together biopharma, diagnostic developers, clinical providers, payers, and regulators with a shared goal: to align on actionable strategies that accelerate the development and adoption of liquid-based biomarkers, driving smarter, faster, and more scalable oncology drug development.

Join **250+** leading minds in **Precision Medicine**, **Translational Science** and **Diagnostics** to gain the insights and partners you require to enable more confident decision-making at every stage of development – ensuring timely, accessible and affordable precision oncology treatments for unmet patient needs.

Regardless of your therapeutic indication or modality, if you need deeper insights into patient stratification, more effective monitoring, earlier detection of relapse, or validation of surrogate endpoints, this is your opportunity to:

- **Accelerate clinical development timelines** by embedding liquid biopsy into adaptive trial design for patient stratification, early efficacy assessment and MRD surveillance
- **Enhance translational strategy** with emerging ctDNA, CTC, and multi-omic biomarkers tailored to your modality and indication
- **Navigate evolving regulatory expectations** for biomarker-driven development and companion diagnostic alignment
- **Strengthen reimbursement and commercialization pathways** by generating data that resonates with payers and supports real-world value
- **Establish strategic collaborations** with diagnostics developers and CROs to de-risk development and scale implementation

Key Benefits of Attending

Leverage emerging analytes and cutting-edge technologies to optimize ctDNA integration for dose-finding and pharmacodynamic studies to minimize patient over-treatment, with insights from:

Pfizer
Genentech

Unleash deeper resolution into patient and tumor heterogeneity with next-generation methylation profiling to refine stratification and predictive biomarker strategies to prevent costly late-stage trial failures, with exciting data from:

ORIC Pharmaceuticals
AstraZeneca

Expedite global clinical trials by harmonizing regulatory pathways for liquid biopsy use to reduce delays and uncertainty, accelerate approvals, and reach patients faster, with key strategies by:

GSK
Bristol Myers Squibb

Refine the validation of MRD as a surrogate endpoint, paving the way for expanded approvals in hematologic malignancies and a first solid tumor indication to transform cancer treatment, explored by:

REGENERON
AKAMIS BIO

Discover the expanding frontiers of liquid biopsy as blood-based biomarkers reshape early detection and monitoring in broader disease applications, unlocking novel therapeutic avenues, discussed by:

AMGEN
Lilly

+1 617 455 4188 info@hansonwade.com
www.lbx-summit.com Biomarkers & Companion Diagnostics
hansonwade

More Than Just Another Conference

10th Anniversary Liquid Biopsy for Precision Oncology Summit

February 3-5, 2026
La Jolla, San Diego, CA

Unforgettable Content

Confronting Complexity: Defining the Next Decade of Liquid Biopsy in Precision Oncology

Steffan Ho, Vice President, Translational Oncology, **Pfizer**

Building Standardized ctDNA & MRD Strategies to Accelerate Clinical Development of Immune-Based Therapies

Cedric Dos Santos, Global Product Leader, **AstraZeneca**

Translating MRD into Regulatory Evidence: Defining the Approval & Adoption Pathway in Solid Tumors

Claudia Dollins, Vice President, Regulatory Affairs, **GSK**

New Companies Featured

Alongside long-standing, consistent attendance from 75% of top 20 big pharma companies, the Summit will be bringing fresh insights including:

85% Brand New Speaker Faculty

20+ Translational & Clinical Case Studies

14+ Technology-Driven Vendor Presentations

6+ Thought-Provoking Panel Discussions & Interactive Sessions

8+ New Companies, Including:

AKAMIS BIO · bridgebio · Milken Institute · septerna · geneos therapeutics · Revolution Medicines

*Companies attending the Liquid Biopsy for Precision Oncology Summit 2025/2026

+1 617 455 4188 · info@hansonwade.com
www.lbx-summit.com · Biomarkers & Companion Diagnostics

hansonwade

10 Years of Progress, One Defining Mission

From a room of pioneers in 2016, to what is now a global community, the rate of progress and innovation in liquid biopsies is unparalleled. Now, after a decade fuelled with investments, partnerships, collaborations and clinical impact, the **10th Liquid Biopsy for Precision Oncology Summit** is uniting the field to realize its full potential.

Take a look at the milestones this community has hit in just 10 years:



Whilst it is critical to reflect on the progress we have made, it is even more important to set goals for the future ahead that can ensure liquid biopsies reach every patient subtype.

This year, our mission is clear:

01

Accelerate Clinical Adoption: Build consensus on validation, regulatory, and reimbursement strategies to embed liquid biopsy into routine oncology care

02

Drive Standardization: Establish common frameworks for assays, data, and workflows to ensure robust, reproducible, and clinically meaningful results across the field

03

Ensure Global Equity & Access: Champion diverse patient representation, scalable technologies, and international harmonization so that every patient, everywhere, can benefit from liquid biopsy

Together, we have the opportunity to transform liquid biopsy from promise to practice, and from innovation to impact, shaping a future where precision oncology is accessible to all

Join us in 2026 at the world's largest industry gathering for experts in liquid biopsy, and shape the future of precision medicine, today

Your Expert Speakers

Pharma Giants

Amrita Pati
Executive Director of Computational Biology, Precision Medicine
Amgen

Leo Grimaldi
Senior Director, Head of Strategy & Operations, Precision Medicine
Amgen

Cedric Dos Santos
Global Product Leader
AstraZeneca

Jonathan Baden
Executive Director & Head, Precision Medicine
Bristol Myers Squibb

Michelle Neff
Associate Vice President, Global Regulatory Affairs, Diagnostics & Companion Diagnostics
Eli Lilly

Yanwen Jiang
Distinguished Scientist
Genentech

Claudia Dollins
Vice President, Global Regulatory Affairs
GSK

David Weingeist
Scientific Director, Oncology Diagnostics Leader
Johnson & Johnson

Partha Das
Global Medical Director - Precision Medicine
Johnson & Johnson

Fernando Cruz-Guilloty
Director - Oncology Precision Medicine & Lung Franchise Lead
Johnson & Johnson

Cynthia Sandoval
Senior Director, Clinical Biomarker Development
Eli Lilly

Steffan Ho
Vice President, Translational Oncology
Pfizer

Achim Moesta
Executive Director, Head of Oncology Precision Medicine
Regeneron

Innovative Biotech

Oliver Rosen
Chief Medical Officer
Akamis Bio

Paul Robbins
Vice President, Translational Sciences
Allogene Therapeutics

Joan Chen
Executive Director, Bioinformatics
Boundless Bio

Hua Gong
Vice President, Translational Medicine
BBOT (BridgeBio Oncology Therapeutics)

Ildiko Csiki
Chief Medical Officer
Geneos Therapeutics

Anneleen Daemen
Executive Director, Translational Medicine
Oric Pharmaceuticals

Zoe June Assaf
Senior Director, Cancer Genomics & Emerging Technologies
Revolution Medicines

Amer Mirza
Vice President, Disease Biology & Translational Sciences
Septerna

Jelveh Lameh
Head, Translational Research
Zai Laboratory

Your Expert Speakers

Leading Voices

Lauren Leiman
Executive Director
BLOODPAC

Hadly Clark
Director
FasterCures, Milken Institute

Anjee Davis
Chief Executive Officer
Fight CRC

Daad Abighanem
Cancer Patient/Survivor
Fight CRC

Anthony Chi
Medical Director
Kaiser Permanente

Daniel Kim
Assistant Professor & Co-Chair
UC Santa Cruz & NIH Liquid Biopsy Scientific Interest Group

Hatim Husain
Professor of Medical Oncology
UC San Diego

Pioneering Solution Providers

FOUNDATION MEDICINE®
GUARDANT
natera
Myriad genetics
TEMPUS
CARIS LIFE SCIENCES
Personalis
BIOIVT ELEVATING SCIENCE
PILLAR BIOSCIENCES
Burning Rock Dx
biodesix
BILLION TO ONE
labcorp
SAGA DIAGNOSTICS
GRAIL
Predicine



Pre-Conference Day
Tuesday, February 3, 2026

10am-8pm

Kick off your summit experience by registering your interest to join **Personalis**, **Natera** and **Guardant Health** for deep-dive engagers designed to give you an inside look at their latest technologies, how they are being applied across biopharma, and the exciting impact they are already having on the field.

These workshops go beyond standard presentations - they are built to be interactive, practical and directly relevant to your work. You'll gain early access to insights that will shape the discussions across the main conference days, while having the chance to put your own questions directly to the experts driving these advances. **What to expect:**

Expert-led presentations

showcasing cutting-edge tools and data that you could leverage for your pipeline

Interactive roundtable discussions

to share challenges and compare approaches with peers, giving you strategies to overcome bottlenecks for your trial

Thought-provoking panels

bringing together multiple perspectives to tackle key questions head-on

Join these sessions to get ahead of the conversation, deepen your understanding of the technology landscape, and make valuable connections before the main conference begins.

Register your interest to join the Pre-Conference Day Engagers:

Personalis

Join **Personalis** for a deep dive engager into their latest technologies and approaches, and explore how they are shaping the future of precision oncology

natera

Hear from **Natera** as they share insights during this gripping engager, into their newest innovations and real-world applications driving progress in liquid biopsy

GUARDANT

Engage with **Guardant Health** in an interactive engager uncovering cutting-edge solutions and the impact they are having across biopharma and clinical practice

Please note: Attendance at these sessions is subject to availability and partner approval

Conference Day One
Wednesday, February 4, 2026

7.30 Morning Check-In & Coffee

8.15 Chair's Opening Remarks

Transforming a Decade of Liquid Biopsy Progress into Routine Clinical Impact for Every Patient

Daad Abighanem
Cancer Patient/Survivor
Fight CRC

8.20 **The Real-World Impact of Liquid Biopsy: The Patient Voice**

As we open the 10th Liquid Biopsy for Precision Oncology Summit, we set aside the innovation and technology to begin with the perspective that matters most: the patient voice

8.30 **10 Years of Liquid Biopsy: Igniting a New Era in Precision Oncology**

Jon Baden
Executive Director & Head of Precision Medicine
Bristol Myers Squibb

- Highlighting key scientific, technological, and regulatory milestones that have shaped the past decade of liquid biopsy innovation
- Identifying the most pressing challenges that still hinder broader adoption across trial phases, tumor types, and clinical settings
- Outlining the next strategic priorities needed to ensure liquid biopsies become a standard, validated tool for patient selection, monitoring, and treatment optimization in every clinical trial

FOUNDATION MEDICINE

9.00 **Presentation Details to be Announced**

Steffan Ho
Vice President – Translational Oncology
Pfizer

9.30 **Confronting Complexity: Defining the Next Decade of Liquid Biopsy in Precision Oncology**

- Confronting the translational hurdles that limit liquid biopsy adoption in drug development, from tumor heterogeneity and assay sensitivity to cost and trial feasibility
- Integrating emerging technologies such as methylation profiling and AI with the rigor required for clinical validation in oncology trials
- Defining how pharma decision-making will shape the path from exploratory assays to scalable, routine tools that deliver real patient impact

GUARDANT

10.00 **Presentation Details to be Announced**

10.30 Morning Break & Speed Networking

As the liquid biopsy community comes together for the 10th anniversary meeting, this dedicated session is designed to help you build meaningful new connections. All attendees will have the chance to meet peers across pharma, biotech, diagnostics and academia, ensuring valuable relationships that extend beyond the summit.

Standardizing Liquid Biopsies to Drive Reliable, Scalable Adoption Across Trials & Clinical Practice

Lauren Leiman
Executive Director
BLOODPAC

11.30 **Interactive Session: Breaking Down Standardization Barriers Through Consistent Terminology & Metrics to Boost Liquid Biopsy Adoption**

- What are the key roadblocks that continue to hinder standardization across liquid biopsy platforms, assays, and reporting?
- Establishing shared definitions, thresholds, and response criteria to align a fragmented field
- Building a practical roadmap for standardization, including actionable milestones and measurable impact to track progress and build confidence

natera

12.00 **Presentation Details to be Announced**

Conference Day One
Wednesday, February 4, 2026

12.30 Panel Discussion: Bridging the Gap from Innovation to Access by Aligning Standardization, Policy & Reimbursement for Liquid Biopsy

- Uncovering how inconsistent definitions, metrics, and data standards are hindering payer confidence and policy support for liquid biopsy
- Exploring the role of pre-competitive collaboration in driving standardization to unlock broader reimbursement and clinical adoption
- Identifying immediate policy actions and evidence needs to align stakeholders and accelerate access to serial testing and early detection

Hadly Clark
Director
Faster Cures - Milken Institute

Anthony Chi
Medical Director
Kaiser Kermanente

Amrita Pati
Executive Director of Computational Biology, Precision Medicine
Amgen

TEMPUS

1.00 Presentation Details to be Announced

1.30 Lunch Break & Networking

Track A: Preclinical Development & Early Translational

Track Chair: Amer Mirza, Vice President, Disease Biology & Translational Sciences, **Septerna**

Embedding Robust Analytical Validation into Translational Studies to Drive Clinical Success

2.20 Advancing Precision Oncology through ctDNA Dynamics

- Exploring how ctDNA dynamics, including methylation patterns, can be leveraged to evaluate therapeutic response and inform treatment decisions
- Discussing the translational value of ctDNA analyses in uncovering mechanisms of resistance and guiding precision-oriented therapies
- Highlighting opportunities to integrate ctDNA into routine clinical workflows to better monitor tumor evolution and improve outcomes for patients with hard-to-treat cancer

Hatim Hassain, Professor of Medical Oncology, **UC San Diego**

2.45 Presentation Details to be Announced

BIOIVT
ELEVATING SCIENCE®

Track B: Clinical Development & Commercialization

Track Chair: Amrita Pati, Executive Director of Computational Biology, Precision Medicine, **Amgen**

Driving Clinical Validation to Enhance Decision-Making & Accelerate Diagnostic Approval

2.20 Utility of ctDNA for Response Assessment of Solid Tumors Treated with Personalized Cancer Immunotherapy

- Demonstrating how ctDNA identifies molecular response and tracks response duration where MRI-based RECIST lacks clarity
- Leveraging ctDNA alongside imaging to enable earlier and more accurate detection of therapeutic benefit in second-line advanced HCC
- Using ctDNA-guided monitoring as an exploratory endpoint to inform trial design, optimize treatment strategies, and lay the groundwork for broader regulatory acceptance

Ildiko Csiki, Chief Medical Officer, **Geneos Therapeutics**

2.45 Presentation Details to be Announced

Personalis

Conference Day One
Wednesday, February 4, 2026

3.15 Fireside Chat: Overcoming Sensitivity & Specificity Challenges to Deliver Reliable Liquid Biopsy Results at Scale

- Defining and achieving the optimal analytical thresholds for sensitivity and specificity in line with intended clinical use – how sensitive is too sensitive?
- Discussing strategies to minimize CHIP related false positives and false negatives without compromising turnaround time or trial feasibility
- Refining analytical validation data strategies to support regulatory submissions, companion diagnostic partnerships, and confident clinical decision-making

Hua Gong, Vice President, Translational Science, **BBOT (BridgeBio Oncology Therapeutics)**

Joan Chen, Executive Director, Bioinformatics, **Boundless Bio**

Moderated by: GRAIL

3.15 Panel Discussion: Clinically Validating Liquid Biopsies for Early Clinical Endpoints to Enhance Patient Selection & Monitoring

- What evidence and study designs are most critical to clinically validate liquid biopsies as early endpoints in trials, and how do these differ across indications?
- How can validated liquid biopsy endpoints improve patient selection and ongoing monitoring to accelerate therapeutic development and decision-making?
- What regulatory, operational, and data-standardization challenges still need to be addressed to ensure liquid biopsy endpoints are trusted and broadly adopted?

Zoe June Assaf, Senior Director, Cancer Genomics & Emerging Technologies, **Revolution Medicines**

Ildiko Csiki, Chief Medical Officer, **Geneos Therapeutics**

Partha Das, Global Medical Director - Precision Medicine, **Johnson & Johnson**

3.45 Presentation Details to be Announced

PILLAR BIOSCIENCES

3.45 Presentation Details to be Announced

labcorp

4.15 Afternoon Networking Break

Harnessing Novel AI, Methylation & Cutting-Edge Technology to Unlock Unprecedented Liquid Biopsy Insights

5.15 Leveraging Mutation & Methylation-Based ctDNA Profiling to Capture Tumor Heterogeneity & Enhance Clinical Readouts

- Demonstrating how broader ctDNA panels extend beyond single-gene tracking in advanced cancer, as a surrogate readout of clinical efficacy and to reveal tumor heterogeneity and evolving drivers of resistance
- Lessons from applying methylation-based sequencing approaches in oncology trials, including challenges in data interpretation and reporting
- Opportunities and limitations of integrating fragmentomics insights derived from methylation data to complement response monitoring in advanced disease

Anneleen Daeman, Executive Director of Translational Medicine, **ORIC Pharmaceuticals**

Seamlessly Integrating Liquid Biopsies into Clinical Trials to Streamline Multi-Vendor & Operational Barriers

5.15 Building Standardized ctDNA & MRD Strategies to Accelerate Clinical Development of Immune-Based Therapies

- Examining how ctDNA and MRD assays can serve as regulatory-acceptable biomarkers and support commercialization of CAR-T and T-cell engager therapies
- Addressing harmonization challenges across assay platforms and how standardization can streamline late-phase trials and companion diagnostic development
- Exploring opportunities for integrated, multi-omic blood-based assays to provide scalable solutions that meet payer, regulatory, and clinician expectations

Cedric Dos Santos, Global Product Leader, **AstraZeneca**

Conference Day One
Wednesday, February 4, 2026

5.40 Underpinning the Value of Urine for Predictive & Monitoring Biomarkers in Bladder Cancer

- Urine-based LBx for patient selection in bladder cancer
- Implementation of urine-based LBx in clinical practice as a non-invasive testing option
- Future applications of urine-based LBx, including MRD and patient monitoring

David Weingeist, Scientific Director, Oncology Diagnostics Leader, **Johnson & Johnson**

5.40 Liquid Biopsy Across the Drug Lifecycle: Discovery, Differentiation & Adoption

- Showing how Amgen leverages ctDNA and other modalities across discovery, clinical development, and commercialization to accelerate differentiation, regulatory approvals, and market adoption
- Highlighting case studies where ctDNA and liquid biopsy analyses informed dose selection, early efficacy readouts, and patient stratification, directly supporting faster decision-making and clinical success
- Discussing how Amgen generates the biomarker evidence base needed for regulators, payers, and clinicians to embrace liquid biopsy as a standard tool in advancing precision medicine

Amrita Pati, Executive Director of Computational Biology, Precision Medicine, Bioinformatics, **Amgen**

6.05 Drinks Reception, Hosted by Foundation Medicine

FOUNDATION MEDICINE

7.05 Evening Engager, Hosted by Foundation Medicine

This exclusive session offers pharma leaders a unique opportunity to engage directly with Foundation Medicine and each other in a focused networking environment. Building on the day's discussions, the engager will spark conversation on the evolving role of liquid biopsy in oncology and provide a platform to explore future partnerships, collaborations and strategic priorities.

Please note: Attendance at this session is subject to availability and partner approval

> "An excellent conference. It was a good mix of topics broadly relevant to the community covered in plenary sessions, more specialized options in two parallel tracks, and easy access to exhibitors"
>
> Past Speaker, Executive Director – Translational Medicine, **Oric Pharmaceuticals**

Conference Day Two
Thursday, February 5, 2026

8.00 Morning Check-In & Coffee

8.20 **Chair's Opening Remarks**

Ensuring MRD Clears Regulatory, Data & Adoption Hurdles to Become a Widely Accepted Surrogate Endpoint in Clinical Trials

Claudia Dollins
Vice President, Regulatory Affairs
GSK

8.30 **Translating MRD into Regulatory Evidence: Defining the Approval & Adoption Pathway in Solid Tumors**

- Addressing analytical and clinical validation standards required to support regulatory review of MRD assays in oncology drug development
- Integrating MRD into trial design to generate evidence packages that enable regulatory qualification as surrogate endpoints
- Aligning regulatory and payer expectations to accelerate acceptance of MRD as a decision-making tool in routine oncology practice

CARIS LIFE SCIENCES

9.00 **Presentation Details to be Announced**

9.30 **Panel Discussion: Accelerating the Use of MRD as a Surrogate Endpoint Across Indications**

- Leveraging existing MRD evidence from hematology (e.g. multiple myeloma) to inform regulatory and policy pathways in new settings
- Driving alignment on assays, thresholds, endpoints, and timepoints to ensure cross-study comparability and reproducibility
- Building collaborative frameworks and secure data-sharing models to generate the robust evidence required by regulators and payers

Achim Moesta
Executive Director, Head of Oncology Precision Medicine
Regeneron

Cedric Dos Santos
Global Product Leader
AstraZeneca

Fernando Cruz-Guilloty
Director - Oncology Precision Medicine & Lung Franchise Lead
Johnson & Johnson

Myriad genetics

10.00 **Presentation Details to be Announced**

10.30 Morning Refreshments & Networking Break

Conference Day Two
Thursday, February 5, 2026

Track A: Preclinical Development & Early Translational

From Exploratory Tools to Accepted Endpoints: Unlocking the Path for ctDNA & MRD in Solid Tumors

11.00 The Evolution of The ctDNA Assays – From Initial Clinical & Regulatory Utility to a Potential Innovative MRD Endpoint in Solid Tumor Indications

- Clinical and regulatory utility of first generation ctDNA assays
- The need for innovative endpoints and important advancements of ctDNA assays to serve as MRD assays
- An example of a potential pathway to establish ctDNA for MRD testing in a solid tumor indication

Oliver Rosen, Chief Medical Officer, **Akamis Bio**

11.25 Presentation Details to be Announced

biodesix

11.55 From Assay to Action – Making MRD a Practical Tool for Treatment Decisions in Hematology

- Bridging assay development and translational research to define clinically meaningful MRD cutoffs and endpoints
- Designing MRD-guided clinical trials to inform treatment decisions, including escalation, consolidation & de-escalation strategies
- Addressing turnaround time, cost and implementation challenges to ensure MRD assays can move fri om trials into routine practice

Yanwen Jiang, Distinguished Scientist, **Genentech**

12.20 Presentation Details to be Announced

Predicine

Track B: Clinical Development & Commercialization

Navigating Regulatory & Policy Hurdles to Accelerate Global Adoption of Liquid Biopsies

11.00 Navigating the Complex, Uncertain Regulatory Environment to Expedite Global Patient Access to Liquid Biopsy Testing

- How to drive global approvals – and expedited approvals – for liquid biopsies
- Understanding evolving global regulatory landscape and call for harmonization
- Emphasizing the importance of early regulatory considerations in clinical studies

Michelle Neff, Associate Vice President, Global Regulatory Affairs, Diagnostics & Companion Diagnostics, **Eli Lilly**

11.25 Presentation Details to be Announced

Burning Rock Dx

11.55 Roundtable Discussion: Designing Clinical Trials with MRD as a Patient Identification Tool to Transform Precision Oncology

- What are the biggest opportunities and limitations of leveraging MRD as a patient identification tool compared with its use for monitoring or as a trial endpoint?
- How are pharma and biotech teams approaching assay selection given variability in MRD sensitivity and methodologies?
- What practical challenges – regulatory, operational, or clinical – remain for embedding MRD-driven patient identification into trial design at scale?

Paul Robbins, Vice President, Translational Sciences, **Allogene Therapeutics**

12.20 Session Available for Partnership

Inquire to Learn More

12.30 Lunch Break & Networking

Conference Day Two
Thursday, February 5, 2026

Unlocking the Potential of CTCs, Extracellular Vesicles, miRNAs & Proteins to Transform Clinical Decision Making

1.30 RNA Liquid Biopsy Technology for Precision Oncology

- Utilizing nanopore sequencing to discover over 250,000 novel RNA biomarkers of precancer and cancer
- Training machine learning models using novel RNA features to classify precancer and cancer with near perfect sensitivity and specificity
- Discovering novel therapeutic targets and RNA biomarkers for precision oncology

Daniel Kim, Assistant Professor & Co-Chair, **UC Santa Cruz & NIH Liquid Biopsy Scientific Interest Group**

1.55 Presentation Details to be Announced

BILLION TO ONE

2.25 Expanding the Role of Emerging Analytes in Liquid Biopsy to Strengthen Translational Oncology Studies

- Exploring how protein, RNA and DNA in circulation can provide value in early-phase solid tumor studies
- Assessing the unique opportunities and limitations of protein-based analysis compared with nucleic acids
- How exploratory analytes can complement DNA-based approaches to support ADC development and broader translational insights

Jelveh Lameh, Head, Translational Research, **Zai Lab**

2.50 Session Available for Partnership

Inquire to Learn More

Advancing Reimbursement, Access & Adoption to Deliver Liquid Biopsies to Every Patient in Need

1.30 Tackling Policy Issues to Ensure Patient Access to Testing & Facilitate Longitudinal Monitoring

- Assessing the limitations of the current policy environment for liquid biopsies, especially for serial monitoring
- How to influence and overcome policy issues preventing patient access to therapeutics
- What are the realistic milestones to hit to expedite better patient access to better drug-diagnostics?

Hadly Clark, Director, Faster Cures, **Milken Institute**

1.55 Session Available for Partnership

Inquire to Learn More

2.25 Empowering Clinicians to Confidently Integrate Liquid Biopsies into Everyday Practice

- Addressing knowledge gaps by providing clear, accessible education on interpreting LBx results and linking them to treatment decisions
- Collaborating with medical societies to embed LBx guidance into specialty guidelines and continuing medical education programs
- Building trusted, ongoing communication channels between diagnostics developers, pharma, and front-line clinicians

Anjee Davis, Chief Executive Officer, **FightCRC**

2.50 Presentation Details to be Announced

SAGA DIAGNOSTICS

3.20 Afternoon Networking Break

Conference Day Two
Thursday, February 5, 2026

New Frontiers: Charting the Next Era of Liquid Biopsies to Transform Medicine Beyond Cancer

Cynthia Sandoval
Senior Director, Clinical Biomarker Development
Eli Lilly

3.50 **New Frontiers in Plasma-Based Diagnostics for Alzheimer's Evaluation**

- Advancements in Alzheimer's Diagnostics: The presentation explores the multi-step process of diagnosing Alzheimer's Disease (AD), emphasizing the role of various clinicians and the use of CSF testing and PET neuroimaging, and the overall importance of biomarkers in evaluating AD pathology
- Biomarker Innovations and Applications: The presentation delves into the progress towards a biological definition of AD, categorizing biomarkers into amyloid plaques, tau, and neurodegeneration. It discusses the emerging use of blood-based biomarkers (BBMs) for evaluating AD pathology, including their advantages, challenges, and the need for standardization in plasma biomarker testing
- Future Directions and Recommendations: The presentation outlines the rationale for focusing on specific plasma markers like P-tau217, the performance recommendations for BBMs, and the dual cut-point approach to achieve high sensitivity and specificity. It also presents data on commercially available plasma P-tau217 tests and recent updates to guidelines

Leandro Grimaldi
Senior Director, Head of Strategy & Operations, Precision Medicine
Amgen

4.20 **Rethinking Strategy: Moving Beyond Disease Stage with AI-Enabled Translational & Retrospective Drug Development**

- Challenge traditional disease stage–focused development by adopting strategies that transcend indication silos
- Explore how AI can act as a disruptive enabler to reimagine how translational data is collected, integrated, and applied
- Demonstrate how these combined approaches can retrospectively inform new molecule design and accelerate the next generation of therapies

4.50 **Chair's Closing Remarks & End of Conference**

> "The speaker presentations were excellent, and the selection was comprehensive and very current. The blend of regulatory sciences and relevant scientific innovation was unique and provided one of the best holistic experiences I've had in attending an industry conference"
>
> Past Attendee, Senior Manager of Digital Innovation, **Pfizer**

2026 Partners

Expertise Partners

FOUNDATION MEDICINE®
GUARDANT™
natera®
Myriad genetics
TEMPUS
CARIS LIFE SCIENCES

Program Partners

Personalis
BIOIVT ELEVATING SCIENCE®
PILLAR BIOSCIENCES
Burning Rock Dx
biodesix®
BILLION TO ONE
labcorp
SAGA DIAGNOSTICS

Panel Partner

GRAIL

Spotlight Partner

Predicine

Exhibition Partner

ALMAC

Get Involved

Sam Sarwar
Senior Commercial Director
+1 617 455 4188
sponsor@hansonwade.com

Lead the Charge – Drive Liquid Biopsy Innovation

10th Liquid Biopsy for Precision Oncology Summit
February 3-5, 2026
La Jolla, San Diego, CA

Your Global Platform to Foster New & Existing Relationships within the Rapidly Growing Liquid Biopsy Space

With major collaborations, regulatory milestones, and acquisitions fuelling momentum, investment and partnerships in liquid biopsy are surging. The field is at a critical moment on the path to routine clinical adoption - making now the time to step forward as a strategic partner and thought leader.

As the leading summit exclusively focused on liquid biopsy in oncology drug development, this meeting offers a unique platform for senior industry leaders to engage directly with the top experts advancing the field. Attendees come with a clear mandate: seeking cutting-edge assays, analytes, technologies, and applications to accelerate clinical development, regulatory approval, and commercialization. This is your opportunity to showcase solutions that directly meet those needs and position your company as essential to progress.

Join 15+ leading diagnostic vendors already confirmed and demonstrate to a packed room of 250+ precision medicine decision-makers why your company should be their next key partner.

Unlock New Connections

Meet senior pharma and biotech leaders looking for liquid biopsy partners to solve trial, regulatory and adoption challenges, ensuring you are on their radar

Showcase Innovation

Lead panels, host workshops or present case studies on ctDNA, MRD, methylation, fragmentomics and AI to an audience of expert decision makers who need your insights for their trials

Guide Pharma's Strategy

Align with Pfizer, Amgen, AstraZeneca, BMS, Regeneron, GSK, Genentech and Eli Lilly at the center of biopharma decision-making, directly proving your expertise and value

Gain Insider Intelligence

Hear directly from KOLs on standardization, reimbursement, MRD acceptance and emerging analytes beyond oncology - and hear from competitors on what they are prioritizing

Seniority of Attendees



- C-Level: 15%
- VP / Head: 25%
- Director: 45%
- Scientist: 15%

Type of Companies Attending



- Drug Developers
- Diagnostic & Service Providers
- Other

*Statistics taken from the 9th Liquid Biopsy for Precision Oncology Summit

Get Involved

Sam Sarwar
Senior Commercial Director
+1 617 455 4188
sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

www.lbx-summit.com/register/

+1 617 455 4188

info@hansonwade.com

Don't Get Left Behind – hear first-hand how the world's leading pharmaceutical, biotech, and diagnostic companies are setting the new standard for liquid biopsy in drug development

Be in the Room Where Decisions are Made – uncover strategies for validation, regulation, and commercialization that will shape the future of precision oncology

Connect With Everyone Who Matters – 250+ senior leaders across pharma, diagnostics, payers, and regulators you simply can't afford to miss

All prices shown in USD. Please visit the website for full pricing options or email info@hansonwade.com

Drug Developers & Research Institutes**	
Conference + Engagers	FREE*
Conference Only	FREE*

Registration is FREE* if you work for a drug developer, research organisation, or academic institution.

*Please note that credit card details will be taken upon registration, and a nominal fee of $0.50 charged. This amount is fully refundable at the end of the month in which the event takes place, provided you attend the event.

**A drug developer, researcher or academic must have a pipeline candidate and/or work for an academic institution, and must not provide solutions or services for a fee to any other company.

Free access is only granted once approval of eligibility is confirmed. Hanson Wade retain the right to reject or cancel your registration if eligibility criteria are not met, and paid registration will then be required to access the event.

Hanson Wade reserves the right to charge free access guests a non-refundable charge of $100 if they do not attend the entire event if they fail to give 7 working days' notice of non-attendance

Vendors & Solution Providers***	Early Bird Pricing: Book by Friday, December 12	On the Door Pricing
Conference Only	$3,499 (save $500)	$3,999

***Service and Solution Providers refer to all employees from Consultancies, CRO, Software, R&D, Diagnostic, or Pre-Clinical Service Provider organisations who partner with, or provide services to, drug developers and/or research organisations.

Team Discounts***

- **10% discount – 3 Attendees**
- **15% discount – 4 Attendees**
- **20% discount – 5+ Attendees**

***Please note that discounts are only valid on paid passes when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: info@hansonwade.com



Venue

San Diego Marriot La Jolla

4240 La Jolla Village Dr, La Jolla, CA 92037, United States

www.marriott.com/en-us/hotels/sanlj-san-diego-marriott-la-jolla/own/